GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Beneish M-Score

Mapi - Pharma (Mapi - Pharma) Beneish M-Score : 0.00 (As of May. 30, 2024)


View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Mapi - Pharma's Beneish M-Score or its related term are showing as below:

During the past 3 years, the highest Beneish M-Score of Mapi - Pharma was 0.00. The lowest was 0.00. And the median was 0.00.


Mapi - Pharma Beneish M-Score Historical Data

The historical data trend for Mapi - Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Beneish M-Score Chart

Mapi - Pharma Annual Data
Trend Dec12 Dec13 Dec14
Beneish M-Score
- - -

Mapi - Pharma Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15
Beneish M-Score - - - - -

Competitive Comparison of Mapi - Pharma's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mapi - Pharma's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Beneish M-Score falls into.



Mapi - Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Mapi - Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec14) TTM:Last Year (Dec13) TTM:
Total Receivables was $0.93 Mil.
Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Total Current Assets was $3.35 Mil.
Total Assets was $9.86 Mil.
Property, Plant and Equipment(Net PPE) was $6.50 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.28 Mil.
Selling, General, & Admin. Expense(SGA) was $3.34 Mil.
Total Current Liabilities was $4.26 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was $-6.44 Mil.
Gross Profit was $0.41 Mil.
Cash Flow from Operations was $-6.19 Mil.
Total Receivables was $0.80 Mil.
Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Total Current Assets was $9.52 Mil.
Total Assets was $16.14 Mil.
Property, Plant and Equipment(Net PPE) was $6.61 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.28 Mil.
Selling, General, & Admin. Expense(SGA) was $2.03 Mil.
Total Current Liabilities was $5.71 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.928 / 0) / (0.801 / 0)
= /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (0 / 0)
= /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3.351 + 6.496) / 9.858) / (1 - (9.52 + 6.607) / 16.136)
=0.001116 / 0.000558
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.279 / (0.279 + 6.607)) / (0.275 / (0.275 + 6.496))
=0.040517 / 0.040614
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3.34 / 0) / (2.027 / 0)
= /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 4.263) / 9.858) / ((0 + 5.707) / 16.136)
=0.432441 / 0.353681
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-6.444 - 0.405 - -6.186) / 9.858
=-0.067255

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


Mapi - Pharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Mapi - Pharma (Mapi - Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.

Mapi - Pharma (Mapi - Pharma) Headlines